## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.5% below STRENGTH zone (4.0-10.0%); PEG 1.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($239.63)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. ResMed director Farrell sells $502k in stock**
- Source: Investing.com | 20251204T190820 | Neutral | Relevance: 100%
- ResMed Inc. Director Peter C. Farrell sold 2,000 shares of company stock for $502,940 on December 3, 2025, under a pre-arranged trading plan. Following this transaction, Farrell directly owns 68,773 shares. This sale comes as ResMed recently reported strong Q4 2025 revenue of $1.35 billion, exceeding analyst expectations, although the stock saw a slight pre-market decrease.

**2. Resmed CFO Sandercock sells $244,160 in stock**
- Source: Investing.com | 20251202T162900 | Somewhat-Bullish | Relevance: 100%
- Resmed CFO Brett Sandercock sold 1,000 shares of RMD stock for $244,160 on December 1, 2025, through a Rule 10b5-1 plan. Despite the sale, the stock has risen, and InvestingPro analysis suggests ResMed is undervalued with "GREAT" financial health. The company also reported strong Q4 2025 revenue of $1.35 billion, surpassing analyst forecasts.

**3. 1,187,798 Shares in ResMed Inc. $RMD Acquired by Norges Bank**
- Source: MarketBeat | 20251202T113256 | Somewhat-Bullish | Relevance: 100%
- Norges Bank acquired a significant new stake of 1,187,798 shares in ResMed Inc. (NYSE:RMD) during Q2, valued at approximately $306.45 million. This acquisition represents about 0.81% of the company, highlighting institutional confidence in the medical equipment provider. ResMed recently reported strong Q3 earnings, exceeding revenue and EPS estimates, and has a consensus "Moderate Buy" rating from analysts.

**4. ResMed Inc. Reports Changes in Beneficial Ownership**
- Source: MSN | 20251202T071041 | Somewhat-Bullish | Relevance: 100%
- The article reports changes in beneficial ownership for ResMed Inc., specifically detailing recent insider transactions. It highlights the acquisition of shares by Director John Joseph Lyons and presents the total holdings of various insider types, including officers, directors, and the top 10 shareholders.

**5. ResMed director Farrell sells $502k in stock By Investing.com**
- Source: Investing.com UK | 20251204T190940 | Neutral | Relevance: 100%
- ResMed Inc. Director Peter C. Farrell sold 2,000 shares of company stock for over $502,000, executed under a pre-arranged trading plan. This sale leaves Farrell with 68,773 shares directly owned. The transaction followed ResMed's Q4 2025 earnings report, which exceeded revenue expectations despite a slight stock decrease.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.3%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Forward P/E 20.9x stretched relative to 10% growth. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.7B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 20.9 |
| Current P/E | 23.1 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.3% to -1.5% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. MACD histogram positive (1.06), confirming momentum. RSI neutral at 47. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.49% (CS: 39) | Neutral |
| RSI_14 | 47.3 | Neutral |
| MACD Histogram | 1.06 | Bullish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 0.967x | Below |
| vs SMA200 | 0.995x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $251.51
- **Stop Loss:** $239.63 (4.7% risk)
- **Target:** $263.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 42
- **Position Value:** $10,563.42
- **Portfolio %:** 10.56%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*